Australien - Englisch - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - clarithromycin, quantity: 500 mg - tablet, film coated - excipient ingredients: sorbic acid; hypromellose; hyprolose; sorbitan mono-oleate; vanillin; purified talc; silicon dioxide; stearic acid; quinoline yellow; propylene glycol; povidone; croscarmellose sodium; titanium dioxide; magnesium stearate; microcrystalline cellulose - klacid (clarithromycin) is indicated for use in adults and children older than 12 years for the treatment of mild to moderately severe infections caused by susceptible strains of the designated micro-organisms in the conditions listed below: 1. acute streptococcal pharyngitis; 2. community acquired pneumonia due to chlamydia pneumoniae, mycoplasma pneumoniae, legionella pneumophila and streptococcus pneumoniae; 3. uncomplicated skin and skin structure infections due to staphylococcus aureus or streptococcus pyogenes; 4. disseminated or localised mycobacterial infections due to mycobacterium avium or mycobacterium intracellulare and skin and skin structure infections due to mycobacterium chelonae. clarithromycin should be used in combination with other antimycobacterial agents. 5. prevention of disseminated mycobacterium avium complex infection in hiv-infected adults with cd4 lymphocyte counts of < 75 cells/cubic mm. (see precautions) disseminated infection due to mycobacterium avium complex should be excluded by a negative blood culture prior to commencement of prophylaxis. 6. acute bacterial exacerbation of chronic bronchitis due to haemophilus influenzae, moraxella catarrhalis or streptococcus pneumoniae; 7. combination therapy for the treatment of peptic ulcer disease associated with helicobacter pylori infection. klacid (clarithromycin) is indicated for use in children for the treatment of mild to moderately severe infections caused by susceptible strains of the designated micro-organisms in the conditions listed below: 1. acute streptococcal pharyngitis and tonsillitis caused by streptococcus pyogenes; 2. community acquired pneumonia including infections due to chlamydia pneumoniae, mycoplasma pneumoniae and legionella pneumophila; 3. skin and skin structure infections (eg impetigo); 4. disseminated or localised infections due to mycobacterium avium or mycobacterium intracellulare in immunocompromised children, including those with hiv infection or aids. 5. acute otitis media. note: 1. penicillins are the drug of first choice in the treatment of acute otitis media. 2. penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections including prophylaxis of rheumatic fever. clarithromycin appears to be as effective as phenoxymethylpenicillin in the eradication of streptococci from the nasopharynx, however substantial data establishing the efficacy of clarithromycin in the subsequent prevention of rheumatic fever are not available at present. 3. there is insufficient evidence of efficacy to support the use of klacid in acute bronchitis in young children. 4. the data presented on infections of skin and skin structure were confined largely to mild to moderate infections such as impetigo.

Malta - Englisch - Medicines Authority

mylan ire healthcare limited unit 35/36, grange parade, baldoyle industrial estate, dublin 13, ireland - clarithromycin - coated tablet - clarithromycin 250 mg - antibacterials for systemic use

Malta - Englisch - Medicines Authority

mylan ire healthcare limited unit 35/36, grange parade, baldoyle industrial estate, dublin 13, ireland - clarithromycin - coated tablet - clarithromycin 500 mg - antibacterials for systemic use

Malta - Englisch - Medicines Authority

viatris healthcare limited damastown industrial park, mulhuddart, dublin 15, dublin , ireland - coated tablet - clarithromycin 250 mg - antibacterials for systemic use

Malta - Englisch - Medicines Authority

viatris healthcare limited damastown industrial park, mulhuddart, dublin 15, dublin , ireland - coated tablet - clarithromycin 500 mg - antibacterials for systemic use

Singapur - Englisch - HSA (Health Sciences Authority)

abbott laboratories (singapore ) private limited - clarithromycin - tablet, film coated - 500 mg - clarithromycin 500 mg

Armenien - Englisch - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

abbvie s.r.l. - clarithromycin - tablets modified-release film-coated - 500mg

Armenien - Englisch - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

aesica queenborough limited - clarithromycin - tablets modified-release film-coated - 500mg (5/1x5/) in blister, (14/1x14/) in blister

Malta - Englisch - Medicines Authority

neofarma pharmaceuticals limited 42-46, mill street, qormi, qrm 3105, malta - clarithromycin - modified-release tablet film-coated tablet - clarithromycin 500 mg - antibacterials for systemic use

Neuseeland - Englisch - Medsafe (Medicines Safety Authority)

viatris limited - clarithromycin 250mg;  ; clarithromycin 250mg - film coated tablet - 250 mg - active: clarithromycin 250mg   excipient: croscarmellose sodium hydrated silica hyprolose hypromellose magnesium stearate microcrystalline cellulose povidone propylene glycol purified talc quinoline yellow   sorbic acid sorbitan oleate starch stearic acid titanium dioxide vanillin active: clarithromycin 250mg excipient: colloidal silicon dioxide croscarmellose sodium ethanol   hyprolose hypromellose magnesium stearate microcrystalline cellulose povidone propylene glycol purified talc purified water quinoline yellow   sorbic acid sorbitan oleate starch stearic acid titanium dioxide vanillin - klacid tablets are indicated for treatment of infections caused by susceptible organisms. such infections include: · respiratory tract infections including bronchitis, pneumonia, tonsillitis, sinusitis and pharyngitis. · skin and soft tissue infections such as folliculitis, cellulitis and erysipelas. · disseminated or localized mycobacterial infections due to mycobacterium avium or mycobacterium intracellulare. localized infections due to mycobacterium chelonae, mycobacterium fortuitum, or mycobacterium kansasii. · prevention of disseminated mycobacterium avium complex infection in hiv-infected patients with cd4 lymphocyte counts less than or equal to 100/mm3. · clarithromycin in the presence of acid suppression is indicated for the treatment of duodenal ulcer and in reducing the rate of ulcer recurrence.